*Indicates a required field.
Stay informed
Sign up to stay informed!
Sign up for the latest information and updates about Rezdiffra and NASH with scarring* plus ongoing support and resources.
*Moderate to advanced liver scarring (fibrosis).
We use cookies to provide and improve our services.
By using our site, you consent to cookies.
Learn more.
Stay informed
Sign up for the latest information and updates about Rezdiffra and NASH with scarring* plus ongoing support and resources.
*Moderate to advanced liver scarring (fibrosis).
*Indicates a required field.
You are now leaving
Madrigal Pharmaceuticals, Inc. does not review, endorse, or control the content of any non-Madrigal site. Madrigal is not responsible for the accuracy, content, practices, or standards of any non-Madrigal resources accessed through a link on this site.
You are now leaving
Madrigal Pharmaceuticals, Inc. does not review, endorse, or control the content of any non-Madrigal site. Madrigal is not responsible for the accuracy, content, practices, or standards of any non-Madrigal resources accessed through a link on this site.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects of Rezdiffra include diarrhea, nausea, itching, stomach pain, vomiting, dizziness, and constipation.
These are not all the possible side effects of Rezdiffra. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Madrigal Pharmaceuticals, Inc. at 1-800-905-0324.
Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.
This indication is approved based on improvement of MASH and liver scarring (fibrosis). There are ongoing studies to confirm the clinical benefit of Rezdiffra.
Please see the accompanying full Prescribing Information, including Patient Information, for Rezdiffra.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects of Rezdiffra include diarrhea, nausea, itching, stomach pain, vomiting, dizziness, and constipation.
These are not all the possible side effects of Rezdiffra. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Madrigal Pharmaceuticals, Inc. at 1-800-905-0324.
Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.
This indication is approved based on improvement of MASH and liver scarring (fibrosis). There are ongoing studies to confirm the clinical benefit of Rezdiffra.
Please see the accompanying full Prescribing Information, including Patient Information, for Rezdiffra.